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Abstract
Purpose The inflammatory markers chitinase-3-like protein 1 (CHI3L1) and chitotriosidase (CHIT1) have both been associated
with cardiovascular complications. The aim of this preliminary observational study was to assess the roles and interaction of
obstructive sleep apnea (OSA) severity and body mass index (BMI) with plasma CHI3L1 levels and CHIT1 activity in patients
with moderate to severe OSA. The second aim was to assess the roles and interaction of positive airway pressure (PAP) treatment
and BMI on the expression of the same proteins.
Methods The study included 97 OSA patients with an apnea–hypopnea index (AHI) ≥ 15 and full usage of PAP treatment after
4 months. Plasma CHI3L1 levels and CHIT1 activity were measured before and after treatment.
Results Multiple linear regression analysis demonstrated an independent association of BMI on CHI3L1 levels (p < 0.05) but not
on CHIT1 activity. The OSA severity markers (AHI and oxygen desaturation index) did not independently or in interaction with
BMI levels associate with CHI3L1 levels or with CHIT1 activity (p > 0.05). A two-way repeated measures ANOVA revealed a
significant interaction between PAP treatment effect (before vs. after) and BMI groups (< 35 kg/m2 vs. ≥ 35 kg/m2) on CHI3L1
levels (p = 0.03) but not on CHIT1 activity (p = 0.98).
Conclusions Obesity independently associated with CHI3L1 levels. Association between OSA severity and CHI3L1 levels or
CHIT1 activity (independent of or dependent on obesity level) could not be confirmed. However, decrease was observed in
CHI3L1 levels after PAP treatment in severely obese OSA patients but not in those less obese.
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Introduction
Obstructive sleep apnea (OSA) is a common disorder charac-
terized by periodic reduction (hypopnea) or cessation (apnea)
of airflow due to narrowing of the upper airway during sleep.
OSA can effectively be treated with positive airway pressure
(PAP) treatment [1]. Untreated OSA patients are at increased
risk of developing cardiovascular complications such as hy-
pertension, stroke, and cardiovascular disease [2].
Obesity is an important risk factor for both OSA and car-
diovascular events. Obesity and OSA also activate similiar
biological pathways of sympathetic activity, oxidative stress,
and low-grade systemic inflammation [3]. It has therefore
been a challenge separating the independent roles of OSA
on cardiovascular disorders from those of obesity. It is likely
that the role of OSA in cardiovascular disease is to some
degree dependent on obesity. In our previous publications
[4–6], we have found a moderating effect of obesity on how
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OSA affects both inflammatory-related protein levels, with the
largest effect of OSA in severely obese patients with body
mass index (BMI) ≥ 35 kg/m2. The concept that interaction
between OSA and obesity increases inflammatory response
could shape the design of future treatment clinical trials [3].
The discovery of biomarkers measuring this interaction effect
is therefore of importance as it has the potential of providing
important information about treatment response.
Chitinase-3-like protein 1 (CHI3L1, also known as YKL-
40) and chitotriosidase (CHIT1) are proteins expressed in re-
sponse to inflammation and have both been associated with
cardiovascular disorders [7]. CHI3L1 is a 40-kD glycoprotein
of the glycosyl hydrolase 18 family, secreted by activated
macrophages, chondrocytes, neutrophils, and synovial cells
[8]. The protein is one of four inactive chitinases that bind to
chitin, but has no chitinase activity [9]. Elevated CHI3L1
levels have been associated with aging [10], degree of obesity
[11], diabetes, and cardiovascular complications including
atherosclerosis, acute myocardial infarction, and coronary ar-
tery disease [12]. A few studies [13–16] have also linked
increased CHI3L1 levels to the presence and severity of
OSA, although more research is still needed. CHI3L1 is se-
creted locally at the site of inflammation and not in response to
systemic inflammation like some inflammatory markers (e.g.,
C-reactive protein [CRP]), indicating it could be of additional
clinical use [17]. As an example, one study investigated the
influence of statin treatment on CHI3L1 and high-sensitivity
CRP levels in patients with stable ischemic heart disease
(IHD) [18]. The statin-induced reduction of the two inflam-
matory markers was much more prominent for CHI3L1 than
CRP, indicating difference between the two biomarkers in
relation to their ability to monitor the inflammatory response
in patients with IHD.
CHIT1 is a 50-kDmammalian chitinase of the same family.
Unlike CHI3L1, CHIT1 is an active enzyme, mainly secreted
by activemacrophages and epithelial cells [19]. Previous stud-
ies have demonstrated that high CHIT1 activity is associated
with Gaucher’s disease, atherosclerosis, and type 2 diabetes
[20]. Very little is known about the relationship between
CHIT1 activity and sleep. One previous study [21] linked
CHIT1 activity to insufficient sleep in mice and rats. To our
best knowledge, only one study has investigated the relation-
ship between CHIT1 and OSA. Tamanaha et al. [22] tested
whether plasma CHIT1 activity was related to the presence
and severity of OSA, with results not indicating a significant
association. Similarly, little is known about the relationship
between CHIT1 and obesity. Alanbay et al. [23] found no
significant correlation between CHIT1 activity and BMI.
No studies are available assessing the effect of PAP treat-
ment on change in CHI3L1 levels or CHIT1 activity. The aim
of this preliminary study was to evaluate the roles and inter-
action of OSA severity (AHI, oxygen desaturation index
[ODI]), and obesity (BMI) on CHI3L1 levels and CHIT1
activity in a clinical cohort of patients with moderate to severe
OSA (AHI ≥ 15). The second aim was to assess the roles and
interaction of positive airway pressure (PAP) treatment and
BMI on the expression of the same proteins.
Methods
Participants
A subset of 97 participants were selected from a larger 284
patients study [24]. All the participants had been diagnosed
with OSA in Iceland and referred for PAP treatment to the
Landspitali—The National University Hospital in Iceland
from February 2010 to December 2013. The initial diagnosis
of OSA was defined by AHI ≥ 15 events/h and oxygen
desaturation index (ODI) ≥ 10 events/h. When sleep studies
were rescored, there were however some subjects (n = 9) who
had AHI between 10 and 15 events/h but they were not ex-
cluded from the study. More than 90% of approached subjects
agreed to participate. Selection criteria for the subset used in
this study were as follows: (1) participation in a sleep study
before starting PAP treatment with a recorded apnea–
hypopnea index (AHI) and oxygen desaturation index
(ODI). All participants had moderate to severe OSA (defined
as AHI ≥ 15) as that was a requirement for PAP treatment; (2)
having blood samples taken while untreated and at follow-up;
(3) used PAP treatment for ≥ 20 days and ≥ 4 h per day on
average for the previous 4 weeks; and (5) completion of a 4-
month follow-up as of May 13, 2014. This study was ap-
proved by the National Bioethics Committee and the Data
Protection Authority of Iceland (10-048). Written consent
was obtained from all subjects.
Questionnaires and measurements
A core questionnaire on sleep, health, and medication use was
answered by subjects at baseline and at a 4-month follow-up
(e.g., if they had been diagnosed with hypertension, diabetes
or cardiovascular disease, or other diseases by a physician).
Height and weight were measured for all participants with the
same instruments (a ruler and a scale), after having removed
shoes as well as objects from clothes. Blood was drawn in the
morning from the antecubital vein after overnight fasting, both
at baseline from untreated participants and at follow-up. Prior
to referral for PAP treatment, all subjects had a type 3 sleep
study with a T3 device (NoxMedical, Reykjavik, Iceland), an
Embletta type 3 portable monitor, or an Embla 12-channel
system (Natus Medical Inc., San Carlos, CA, USA). Type 3
portable monitors were used for home sleep apnea testing
(HSAT) as this is the clinical practice in Iceland as it is in
many other countries, e.g., in Europe [25], and accepted by
the AASM in the USA [26]. The study therefore lacks
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electroencephalographic recording and assessment of
arousals. However, the validity of the Nox T3 portable mon-
itoring system for assessing sleep-disordered breathing has
been shownwhen comparedwith polysomnography with sim-
ilar AHI and ODI levels [27, 28]. Also, the respiratory scoring
rules used (requiring 4% oxygen desaturation for hypopnea
events) do not require arousals to assess hypopneas. The same
signals were recorded on all studies. Nasal airflow was record-
ed through a cannula. Chest and abdominal movements were
measured using respiratory inductance plethysmography
belts. Pulse and oxygen desaturation were measured by a fin-
ger probe oximeter based on a four-beat exponential average
(Nonin Medical Inc., Plymouth, MN, USA). Body position
and activity were measured using sensors situated on the
chest. The sleep studies were scored by trained sleep technol-
ogists. Studies had to have ≥ 4 h of scorable oxygen saturation
and more than two out of three respiratory traces: cannula
flow, thorax and respiratory inductive plethysmography belts.
Total analysis time was assessed based on questionnaires and
the sleep technologist’s review of the study. Sleep studies were
scored in accordance with the American Academy of Sleep
Medicine (AASM) 2007 manual [29], using the recommend-
ed hypopnea classification requiring a ≥ 30% drop in respira-
tory flow for ≥ 10 s with ≥ 4% oxygen desaturation.
PAP use
PAP adherence at follow-up was measured objectively by
downloading the mask-on time stored by the PAP unit in the
previous 4 weeks (S8 machines, ResMed, San Diego, CA,
USA). Participants who used PAP for ≥ 20 days and ≥ 4 h
per day on average for the previous 4 weeks were considered
full users.
Biomarker assessment
Blood was collected in BD vacutainers containing EDTA
(BD, Franklin Lakes, NJ, USA), gently inverted 8–10 times,
and placed on ice. Within 1 h of collection, the sample was
spun for 15 min at 1790g in a refrigerated centrifuge. The
samples were kept on ice during aliquoting. After separation,
the plasma samples were stored at − 80 °C.
The CHI3L1 levels in human plasma samples were mea-
sured using a commercially available Sandwich Elisa Duoset
from R&D systems (cat. DY2599, Minneapolis, MN). The
assays were run in 96-well plates (Nunc 442404, MaxiSorp)
using 100 μl of plasma (1:800 dilution) as per manufacturer’s
instructions. For standards, human recombinant CHI3L1 pro-
tein was used at concentrations ranging from 31.25 to
2000 pg/ml. All samples were measured in duplicates.
Chitotriosidase enzyme assay was based on the method
described by Hollak et al. [30] with minor modifications.
Briefly, chitotriosidase activity was determined by incubating
5 μl of plasmawith 100 μl of 22mol/l fluorogenic substrate 4-
methylumbelliferyl β-D-N,N′,N′′-triacetylchitotrioside (Sigma
M5639) in 0.1 M/0.2 M citrate–phosphate buffer (pH 5.2) for
15 min at 37 °C. The reaction was stopped with 200 μl of 1 M
glycine–NaOH buffer (pH 10.6) by mixing at room tempera-
ture. The substrate hydrolysis by chitotriosidase produces the
fluorescent molecule 4-methylumbelliferone, which was
quantified with a fluorometer (Spectramax M3 instrument),
excitation at 360 nm and emission at 450 nm, and compared
with a standard 4-methylumbelliferone (Sigma M1508) cali-
bration curve. Plasma chitotriosidase activity was measured in
triplicates. Inter-assay coefficient of variation (CV) for both
CHI3L1 and CHIT1 was within 20% and intra-assay CV was
within 10%.
Statistical analysis
Descriptive group comparisons were performed using one-
way analysis of variance and chi-square tests for continuous
and categorical variables, respectively. CHI3L1 and CHIT1
were natural log-transformed for all analyses (based on assess-
ment of residual error distribution, thereby permitting para-
metric analysis). The strengths of linear associations among
biomarker values (CHI3L1 levels, CHIT1 activity), BMI, and
OSA severity were assessed using Pearson’s correlation and
multiple linear regression. Paired t test was used to compare
the means of biomarker values before and after PAP treatment.
Independent t test was used to compare the means of biomark-
er values between men and women. A two-way repeated mea-
sures ANOVAwith interaction effects was performed to eval-
uate interaction effects between PAP treatment and BMI
groups on biomarker values. All statistical analyses were per-
formed using SPSS v.23.0 (IBM Corp., Armonk, NY, USA).
To avoid extrapolation beyond the scope of the data, sen-
sitivity analyses were performed excluding those participants
who had OSA severity not found in the other BMI groups [3].
All of the analyses led to the same conclusions as the original
ones, and therefore all participants were used for the final
analyses of the study.
Results
Baseline clinical and biochemical characteristics
Clinical and biochemical characteristics of OSA patients at
baseline, both overall and within different BMI categories,
are presented in Table 1. Severely obese subjects (BMI ≥
35 kg/m2) had more severe OSA (higher AHI and ODI) as
well as higher levels of CHI3L1, compared to patients with
lower BMI (< 30 kg/m2 and 30–35 kg/m2). Furthermore, OSA
patients within the highest BMI group also had a higher prev-
alence of type 2 diabetes compared to the other groups.
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The range in values for AHI was between 15 and
116 events/h; for ODI, between 4 and 113 event/h; and for
BMI, between 24.8 and 53.3 kg/m2.
Association between OSA severity and obesity
with chitinase levels and activity
The correlation between chitinases and OSA severity markers
(AHI, ODI) as well as obesity levels (BMI) was assessed.
BMI was positively correlated with CHI3L1 levels (r = 0.21,
p = 0.04) but not with CHIT1 activity (r = 0.06, p = 0.53). For
OSA severity markers, a tendency for a weak positive corre-
lation was observed with CHI3L1 levels, although not signif-
icant, and no relationship was found with CHIT1 activity
(Fig. 1).
The relationships between the OSA severity markers and
the chitinases were also assessed within the three different
BMI categories. An indication of a specific pattern appeared
for CHI3L1 levels. Although all insignificant (p > 0.05), both
OSA severity markers correlated negatively with CHI3L1
levels within the lower BMI groups (< 30 kg/m2 and 30–
35 kg/m2) but positively within the highest BMI group
(BMI ≥ 35 kg/m2, Fig. S1a and Fig. S2a in supplement). No
effect between OSA severity and CHIT1 activity was found
when assessed within the three the same BMI categories (Fig.
S1b and Fig. S2b in supplement).
To further evaluate how the level of BMI affects the rela-
tionship between OSA severity and chitinases, multiple linear
regression analysis with interaction was performed (Table 2).
The analysis demonstrated independent association of BMI
and age with CHI3L1 levels. Significance (p < 0.05) was
reached, independent of AHI (model 1) or ODI (model 2)
being included in the analysis. Neither AHI nor ODI associ-
ated independently with CHI3L1 levels and the interaction
between the markers and BMI was also non significant
(p > 0.05). No independent association was found with
CHIT1 activity.
The effect of PAP treatment on chitinase levels
and activity
Overall, no significant differences in CHI3L1 levels (3.87 ±
0.05 vs. 3.79 ± 0.05, p = 0.08) and CHIT1 activity (3.17 ±
0.09 vs. 3.20 ± 0.09, p = 0.08) were found among OSA pa-
tients before and after PAP treatment. There was a trend to-
wards an interaction between treatment and BMI, although the
interaction effect did not reach significance (p = 0.08, Fig. S3
in supplement). For an increased power, we also ran the anal-
ysis by combining the two lower BMI groups. Figure 2 pre-
sents differences in CHI3L1 levels and CHIT1 activity before
and after PAP treatment when stratified by two BMI groups
(< 35 kg/m2 and ≥ 35 kg/m2). A two-way repeated measures
ANOVA revealed a significant interaction (p = 0.028) be-
tween the two factors for CHI3L1 levels showing a significant
decrease in CHI3L1 levels for OSA patients with PAP treat-
ment with BMI ≥ 35 only, not those with BMI < 35 (Fig. 2a).
No significant interaction between PAP treatment and BMI
groups (p = 0.976) was found for CHIT1 activity (Fig. 2b).
Four additional repeated measures ANOVA analyses were
also performed, with each analysis excluding a different group
Table 1 Demographics and sleep-disordered breathing data at baseline in the whole cohort and by different BMI levels
All n = 97 BMI < 30 n = 26 BMI 30–35 n = 37 BMI ≥ 35 n = 34 pa
Age (years) 54.4 ± 10.5 56.4 ± 10.2 55.6 ± 10.0 51.6 ± 11.0 0.14
Males (%) 74.2 80.8 78.4 64.7 0.28
BMI (kg/m2) 33.9 ± 5.6 27.9 ± 1.5 32.4 ± 1.4 40.2 ± 4.1 N/A
Sleep-disordered breathing
AHI (events/h) 39.0 ± 22.3 33.8 ± 16.2 34.7 ± 18.9 47.7 ± 27.2 0.02
ODI (events/h) 32.7 ± 21.3 26.8 ± 15.2 26.9 ± 18.2 43.7 ± 24.5 < 0.001
Medical history
Hypertension (%) 66.7 54.2 79.4 62.5 0.11
Cardiovascular disease (%) 3.3 4.0 0.0 6.1 0.37
Stroke (%) 12.6 19.2 10.8 8.8 0.45
Type 2 diabetes (%) 14.6 12.0 5.4 26.5 0.04
Biomarker levels/activity
CHI3L1 (ng/ml)b 3.9 ± 0.5 3.8 ± 0.5 3.8 ± 0.5 4.1 ± 0.5 0.03
CHIT1 (nmol/ml/h)b 3.2 ± 0.9 3.0 ± 1.1 3.3 ± 0.6 3.2 ± 1.1 0.49
Data are presented as mean ± standard deviation or % where indicated
a One-way analysis of variance for continuous variables and Pearson’s chi-square test for percentages for comparison between groups
b Exponentiated mean and 95% confidence interval determined from log-transformed values (i.e., geometric mean)
BMI, body mass index; AHI, apnea-hypopnea index; ODI, oxygen desaturation index; CHI3L1, Chitinase-3-like protein 1; CHIT1, Chitotriosidase
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of patients from the study, to assess the potential confounding
effects of other diseases. Each analysis excluded patients with
hypertension, cardiovascular disease, stroke, or type 2 diabe-
tes. Interaction effects between PAP treatment and the two
BMI groups reached significance for CHI3L1 levels
(p < 0.05) but not for CHIT1 activity, independent of which
patient group was excluded. This is in accordance with the
primary analysis. No significant differences were found be-
tween men and women in CHI3L1 levels at baseline (3.86 ±
0.06 vs. 3.87 ± 0.10, p = 0.99) or after treatment (3.78 ± 0.06
vs. 3.82 ± 0.10, p = 0.72). Despite this lack of difference, sen-
sitivity analysis was performed including men only (n = 72).
The interaction effect for CHI3L1 levels showed a similar
trend as for the main analysis but did not reach significance
(p = 0.20, Fig. S4 in supplement).
Discussion
The results of this study indicate that effects of PAP treatment
on CHI3L1 levels depend on the level of obesity (measured by
BMI) in a population of patients with moderate to severe
OSA. Obesity did also positively associate with the concen-
tration of the same protein. The effect of OSA severity on
CHI3L1 levels, with and without the degree of obesity, was
not significant indicating that the AHI and ODI as markers of
OSA severity may not be appropriate to assess the impact of
OSA on CHI3L1 levels in the same patient populations.
Furthermore, the effect of PAP treatment, degree of obesity,
and OSA severity did not associate with CHIT1 activity.
Few recent studies have demonstrated an independent as-
sociation of both the presence and severity of OSA on serum
Fig. 1 Pearson’s correlation between apnea–hypopnea index (AHI), oxygen desaturation index (ODI), BMI (body mass index) and CHI3L1 levels (a)
and CHIT1 activity (b)
Table 2 Multiple linear
regression models, predicting
plasma CHI3L1 levels and
CHIT1 activity
Log (CHI3L1) levels (ng/ml) Log (CHIT1) activity (nmol/ml/h)
Standardized β (95% CI) p Standardized β (95% CI) p
Model 1 AHI 0.12 (− 0.09–0.33) 0.27 0.01 (− 0.22–0.24) 0.94
BMI 0.24 (0.03–0.45) 0.026 0.06 (− 0.17–0.28) 0.63
BMI× AHI 0.01 (− 0.21–0.22) 0.94 0.06 (− 0.17–0.29) 0.60
Age (years) 0.32 (0.13–0.52) 0.002 0.08 (− 0.13–0.28) 0.48
Model 2 ODI 0.14 (− 0.08–0.36) 0.21 − 0.10 (− 0.34–0.13) 0.40
BMI 0.23 (0.01–0.44) 0.047 0.12 (− 0.12–0.35) 0.34
BMI× ODI 0.01 (− 0.21–0.23) 0.899 0.06 (− 0.18–0.29) 0.65
Age (years) 0.34 (0.14–0.54) 0.001 0.08 (− 0.13–0.29) 0.46
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CHI3L1 levels [13–16]. Our results are not in accordance with
these previous studies as an independent relationship between
OSA severity and CHI3L1 levels could not be confirmed. A
possible explanation is that our sample did only include pa-
tients with moderate to severe OSA, not those with mild OSA
and healthy controls. Our results, on the other hand, confirmed
an independent, positive association of obesity and age with
CHI3L1 levels, which has also been reported in earlier studies
[10, 11, 31].
Obesity is an important risk factor in the pathogenesis of
OSA [32–34]. As obesity and OSA tend to coexist, they can
also independently affect similar biological pathways such as
oxidative stress and inflammation [35–38]. Previous studies
have indicated an accumulation of activated macrophages and
other immune active cells in visceral adipose tissue from
obese subjects as possible sources of inflammatory cytokines,
determining a link between obesity and low-grade inflamma-
tion [39, 40]. It could therefore be hypothesized that the effect
of OSA is amplified by the increased number of inflammatory
cells in fat in the most obese patients [41]. Arnardottir et al. [4]
demonstrated, in a large study based on the Icelandic Sleep
Apnea Cohort, that the independent association of OSAwith
levels of pro-inflammatory cytokines interleukin-6 (IL-6), and
CRP depended on the degree of obesity. These results were
furthermore confirmed in a long-term follow-up [5] where the
increase of interleukin-6 was prevented by PAP treatment, but
only among severely obese patients (BMI ≥ 35 kg/m2).
CHI3L1 has been identified as a major protein expressed in
macrophages among stromal vascular fraction cells in human
visceral adipose tissue [42]. When assesing the role of PAP
treatment and obesity on CHI3L1 levels, our results came to
similar conclusions with these studies. Change in levels of the
protein after PAP treatment did depend on degree of obesity.
Reduction in CHI3L1 levels was found among severely obese
patients (BMI ≥ 35 kg/m2) after treatment but not in those less
obese (BMI < 35 kg/m2).
An interaction effect did not appear between PAP treatment
and obesity regarding CHIT1, as there were no significant
changes in activity after treatment when analyzed by different
BMI categories. Very few studies have examined the relation-
ship between CHIT1 enzyme activity and sleep. A previous
study by Lungato et al. [21] showed association between
CHIT1 plasma levels and paradoxical sleep deprivation in
adult male mice and rats. They found a significant increase
in CHIT1 plasma levels when the animals were subjected to
paradoxical sleep deprivation for 72 h compared to controls.
Because sleep has an important role for the maintenance and
efficiency of the immune system [43, 44], their data suggested
a relationship between sleep and macrophage response, where
CHIT1 activity could possibly serve as a marker for
Fig. 2 Mean ± SEM CHI3L1
levels (a) and CHIT1 activity (b)
before and after PAP treatment by
two BMI groups
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insufficient sleep. To our best knowledge, only one study has
investigated the relationship between OSA and CHIT1.
Tamanaha et al. [22] tested whether plasma CHIT1 activity
was related to the presence and severity of OSA in a Brazilian
cohort, where the results did not indicate a significant associ-
ation. Our results are in accordance with those results: no
association was measured between OSA severity and CHIT1
activity. The relationship did not appear to depend on obesity
either, with no specific interaction effect appearing. To our
best knowledge, it has not been tested if the enzyme is
expressed bymacrophages and endothelial cells in the visceral
adipose tissue.
There are a fewmajor limitations of the present study. First,
this is an observational study, not a randomized controlled
trial, with all participants receiving full PAP treatment.
Therefore, our findings are preliminary and have to be
interpreted with caution. Second, this was a study with a rel-
atively small number of OSA patients and present findings
need to be validated in a larger study. The sample did not
include non-OSA controls or mild OSA patients and the lim-
ited variability in the lower end of OSA severity and BMI
could underestimate associations between the studied vari-
ables. The sample was also relatively homogeneous with
Caucasian and mostly male participants. The results might
therefore not generalize to other more ethnically diversed pop-
ulations or across gender. No difference in serum CHI3L1
levels between males and females have though been found
in previous studies [45]. Third, we did not have other mea-
surements of obesity like visceral fat and waist circumference,
change in BMI during the 4-month treatment period, or con-
centrations of other pro-inflammatory mediators, which may
provide valuable information on a possible role of CHI3L1
and CHIT1 in the progression of OSA. However, our previous
paper assessing the role of different fat measures in inflamma-
tory biomarkers showed that total fat measures such as BMI
were more highly associated with inflammatory levels than
visceral fat levels per se [4]. Fourth, with multiple sensitivity
analyses (excluding each disease), there is an increased risk
of false positive results (type 1 error). By replicating the
study in a larger sample, more information could be fitted
into the statistical model, decreasing the risk of this type of
error. Also, with a larger sample, estimation of coefficients
will be more precise. Finally, residual confounding cannot
be fully excluded as confounding factors were assessed with
crude precision (e.g., having a condition vs. not having a
condition).
In conclusion, this is the first paper to assess the effect of
PAP treatment on CHI3L1 levels and CHIT1 activity in OSA
patients. The results show a decrease in CHI3L1 levels after
4 months of full PAP treatment in severely obese OSA patients
(BMI ≥ 35 kg/m2), but not in those less obese (BMI < 35 kg/
m2). The same effect was not observed with CHIT1 activity.
Obesity and age were independently associated with CHI3L1
levels but not with CHIT1 acitvity. Association between OSA
severity and CHI3L1 levels/CHIT1 activity (independent of or
dependent on obesity) could not be confirmed.
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